Building Blocks Catalog

300 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

1B novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

48B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from February 2024

Recent News

  • 27 March 2024   Press Release

    Enamine Announces Expansion of Its Library Synthesis Capabilities

    March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.

  • 01 March 2024   News

    Enamine and Genez International Announce Strategic Collaboration to Launch ...

    We are excited to announce a strategic collaboration between Enamine, the world's leading provider of chemical building blocks, compound libraries, and biology services, and Genez International, a prominent enterprise with 15 years of experience in cross-border supply management, biopharmaceutical research and development, semiconductor equipment, and high-definition digital imaging systems.

  • 21 February 2024   Press Release

    Cresset Announces Global Collaboration With Enamine on New Virtual ...

    Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative new solutions for the early drug discovery process.

Upcoming events

Melatonin (MT) receptors are established drug targets for aligning circadian phase in disorders of sleep and depression. But there are only a few in vivo hits reported to date. Enamine scientists along with the scientists from UCSF, UNC, USC, and other institutions participated in the research study aimed to fill the gap in therapeutics of these receptors.

150 million make-on-demand compounds from Enamine REAL Database were selected for initial hit finding via ultra-large docking against MT1 receptor. The REAL compounds with a structural fit and chemical novelty were prioritized. These high-ranking hits were delivered by Enamine via parallel synthesis for in vitro screens. Structure-based optimization led to two selective MT1 inverse agonists, topologically unrelated to previously explored chemotypes, that were tested in mouse models of circadian behavior. Unexpectedly, the MT1-selective inverse agonists advanced the phase of the mouse circadian clock, an agonist-like effect eliminated in MT1- but not in MT2-knockout mice.

We are proud to have these findings published in Nature. The results of this and the previous studies illustrate the opportunities for obtaining new, in vivo-active chemotypes from structure-based screens of diverse libraries of make-on-demand compounds.

FOLLOW US